Evidence map›Paper›PMID 35132576›Full record

ArticleWorld journal of pediatrics : WJP2022

ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.

Dinesh Babu Somasundaram, Sheeja Aravindan, Nandita Gupta, Zhongxin Yu, Ashley Baker, Natarajan Aravindan

Abstract readLetter
PubMed Publisher
In one paragraph

Article in World journal of pediatrics : WJP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dinesh Babu SomasundaramDepartment of Radiation Oncology, BMSB 311C, Radiation Biology Laboratory, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Boulevard, Oklahoma City, OK, 73104, USA.
Sheeja AravindanStephenson Cancer Center, Oklahoma City, OK, USA.
Nandita Gupta, Plainsboro, NJ, USA.
Zhongxin YuDepartment of Pathology, BMSB 311C, Radiation Biology Laboratory, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Boulevard, Oklahoma City, OK, 73104, USA.
Ashley BakerDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Natarajan AravindanDepartment of Radiation Oncology, BMSB 311C, Radiation Biology Laboratory, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Boulevard, Oklahoma City, OK, 73104, USA. naravind@ouhsc.edu.ORCID 0000-0001-9150-3911

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2012 to 2022
$21.3M
NIGMS NIH HHS P20 GM103639
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anaplastic Lymphoma KinaseNeuroblastomaN-Myc Proto-Oncogene ProteinGene Expression Regulation, NeoplasticHumansPrognosisReceptor Protein-Tyrosine KinasesALK protein, humanAnaplastic Lymphoma KinaseMYCN protein, humanN-Myc Proto-Oncogene ProteinReceptor Protein-Tyrosine Kinases

Identifiers

PMID35132576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.